Want to see MRKR full AI Analyst Report?
MRKR Stock Chart & Stats
$1.22
$0.00(0.00%)
At close: 4:00 PM EDT
$1.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.81 - $2.46
Previous Close$1.22
Volume42.26K
Average Volume (3M)56.86K
Market Cap
$19.01M
Enterprise Value$16.47
Total Cash (Recent Filing)$11.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,673,126
10 Day Avg. Volume37,502
30 Day Avg. Volume56,863
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside637.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage (no Debt)Zero reported debt meaningfully reduces fixed financing costs and bankruptcy risk, preserving strategic optionality. For a cash-burning clinical-stage biotech, a low-debt structure lowers near-term solvency pressure and gives management flexibility to time dilutive financings or partnerships more deliberately.
Platform-focused Immunotherapy R&DA platform aiming to target multiple tumor-associated antigens is a structurally attractive strategy: it can reduce antigen-escape risk and enable pipeline breadth across hematologic and solid tumors. Long-term, a scalable T-cell platform can support multiple indications and recurring clinical-stage programs.
Board/governance Support And Financing OptionalityShareholder approval for a large increase in authorized shares expands capital-raising and transaction capacity, a durable enabler for financing trials or strategic deals. Coupled with re-elected directors and auditor ratification, this signals governance continuity and capacity to execute funding strategies.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external capital to sustain R&D and trials. Repeated financings can dilute shareholders and distract management; absent a quick path to margin improvement or partnering, cash burn threatens continuity and strategic optionality.
Negative Gross Profit And Large Net LossesNegative gross profit and sizable net losses indicate the core activities are not yet generating sustainable economics. For a clinical-stage biotech, persistent unprofitable operations lengthen the commercialization runway and increase dependence on dilutive funding or value-destructive asset sales.
Declining And Volatile RevenueA small, declining revenue base reflects limited commercial traction and increases operational fragility. Volatile, low revenue magnifies the impact of cash burn and reduces internal funding capacity for clinical programs, making long-term planning and sustained R&D investment more challenging.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics’s price range in the past 12 months?
Marker Therapeutics lowest stock price was $0.81 and its highest was $2.46 in the past 12 months.
What is Marker Therapeutics’s market cap?
Marker Therapeutics’s market cap is $19.01M.
When is Marker Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Marker Therapeutics’s earnings last quarter?
Currently, no data Available
Is Marker Therapeutics overvalued?
According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued.
Does Marker Therapeutics pay dividends?
Marker Therapeutics does not currently pay dividends.
What is Marker Therapeutics’s EPS estimate?
Marker Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marker Therapeutics have?
Marker Therapeutics has 16,673,126 shares outstanding.
What happened to Marker Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Marker Therapeutics?
Currently, no hedge funds are holding shares in MRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(637.70% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
18.09%
Insiders
3.00% Mutual Funds
15.13% Other Institutional Investors
61.22% Public Companies and
Individual Investors